Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amphastar PharmaceuticalsAMPH +1.69%84 3-Year EPS without NRI Growth Rate is 18.20% as of Jun. 2026, which is 40% below its 10-year median of 30.10. GuruFocus rates AMPH with a GF Score™ of 84/100 and a GF Value™ of $35.94 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 786 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 64.12% on this metric.
During the past 12 months, Amphastar Pharmaceuticals's average EPS without NRI Growth Rate was -32.80% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 18.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 39.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Amphastar Pharmaceuticals was 86.90% per year. The lowest was -31.00% per year. And the median was 30.10% per year.
Amphastar Pharmaceuticals (NAS:AMPH) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Amphastar Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
AMPH vs PCRX, COLL, IRWD: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Amphastar Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 18.20% mean?
Amphastar Pharmaceuticals (AMPH) has a 3-Year EPS without NRI Growth Rate of 18.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Amphastar Pharmaceuticals and its competitors. This is 40% below median its historical median of 30.10. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #282 out of 786 companies in the Drug Manufacturers industry, placing it in the top 35.9%.
Is Amphastar Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Amphastar Pharmaceuticals' current 3-Year EPS without NRI Growth Rate of 18.20% is 40% below median its 10-year median of 30.10. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.85. Amphastar Pharmaceuticals' value of 18.20% is 84.8% above this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #282 out of 786 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to PCRX and COLL?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #282 out of 786 companies for 3-Year EPS without NRI Growth Rate. This puts Amphastar Pharmaceuticals in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.85. Amphastar Pharmaceuticals' value of 18.20% is 84.8% above this benchmark. While the company's 10-year median is 30.10 vs. the industry median of 9.85, Amphastar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.85, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current 3-Year EPS without NRI Growth Rate of 18.20% is 84.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is 18.20%, which is 40% below median its own 10-year median of 30.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.94, compared to a current price of $22.93 — trading 36.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 18.20%, which is 40% below median its 10-year median of 30.10 and 84.8% above the Drug Manufacturers industry median of 9.85. Amphastar Pharmaceuticals' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current 3-Year EPS without NRI Growth Rate is 18.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $22.93 is trading 36.2% below its estimated GF Value™ of $35.94.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
3-Year EPS without NRI Growth Rate: 18.20% (40% below median its 10-year median of 30.10)
GF Value™: $35.94 vs. price of $22.93 (36.2% below fair value)
Industry Position: 84.8% above the Drug Manufacturers median (#282 of 786)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
84GF Score
Get the complete analysis for AMPH
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
